130 related articles for article (PubMed ID: 29432733)
1. DOCK1 inhibition suppresses cancer cell invasion and macropinocytosis induced by self-activating Rac1
Tomino T; Tajiri H; Tatsuguchi T; Shirai T; Oisaki K; Matsunaga S; Sanematsu F; Sakata D; Yoshizumi T; Maehara Y; Kanai M; Cote JF; Fukui Y; Uruno T
Biochem Biophys Res Commun; 2018 Feb; 497(1):298-304. PubMed ID: 29432733
[TBL] [Abstract][Full Text] [Related]
2. Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCK1.
Tajiri H; Uruno T; Shirai T; Takaya D; Matsunaga S; Setoyama D; Watanabe M; Kukimoto-Niino M; Oisaki K; Ushijima M; Sanematsu F; Honma T; Terada T; Oki E; Shirasawa S; Maehara Y; Kang D; Côté JF; Yokoyama S; Kanai M; Fukui Y
Cell Rep; 2017 May; 19(5):969-980. PubMed ID: 28467910
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic Differences of Activation of Rac1
Senyuz S; Jang H; Nussinov R; Keskin O; Gursoy A
J Phys Chem B; 2021 Apr; 125(15):3790-3802. PubMed ID: 33848152
[TBL] [Abstract][Full Text] [Related]
4. RAC1P29S is a spontaneously activating cancer-associated GTPase.
Davis MJ; Ha BH; Holman EC; Halaban R; Schlessinger J; Boggon TJ
Proc Natl Acad Sci U S A; 2013 Jan; 110(3):912-7. PubMed ID: 23284172
[TBL] [Abstract][Full Text] [Related]
5. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.
Watson IR; Li L; Cabeceiras PK; Mahdavi M; Gutschner T; Genovese G; Wang G; Fang Z; Tepper JM; Stemke-Hale K; Tsai KY; Davies MA; Mills GB; Chin L
Cancer Res; 2014 Sep; 74(17):4845-4852. PubMed ID: 25056119
[TBL] [Abstract][Full Text] [Related]
6. RAC1 P29S regulates PD-L1 expression in melanoma.
Vu HL; Rosenbaum S; Purwin TJ; Davies MA; Aplin AE
Pigment Cell Melanoma Res; 2015 Sep; 28(5):590-8. PubMed ID: 26176707
[TBL] [Abstract][Full Text] [Related]
7. RAC1mutation is not a predictive biomarker for PI3'-kinase-β-selective pathway-targeted therapy.
Foth M; Parkman G; Battistone B; McMahon M
Pigment Cell Melanoma Res; 2020 Sep; 33(5):719-730. PubMed ID: 32406574
[TBL] [Abstract][Full Text] [Related]
8. The guanine nucleotide exchange factor Tiam1: a Janus-faced molecule in cellular signaling.
Boissier P; Huynh-Do U
Cell Signal; 2014 Mar; 26(3):483-91. PubMed ID: 24308970
[TBL] [Abstract][Full Text] [Related]
9. Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints.
Cannon AC; Budagyan K; Uribe-Alvarez C; Kurimchak AM; Araiza-Olivera D; Cai KQ; Peri S; Zhou Y; Duncan JS; Chernoff J
Oncogene; 2024 Mar; 43(10):729-743. PubMed ID: 38243078
[TBL] [Abstract][Full Text] [Related]
10. Impaired cell death and mammary gland involution in the absence of Dock1 and Rac1 signaling.
Bagci H; Laurin M; Huber J; Muller WJ; Côté JF
Cell Death Dis; 2014 Aug; 5(8):e1375. PubMed ID: 25118935
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.
Mar VJ; Wong SQ; Logan A; Nguyen T; Cebon J; Kelly JW; Wolfe R; Dobrovic A; McLean C; McArthur GA
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1117-25. PubMed ID: 25043693
[TBL] [Abstract][Full Text] [Related]
12. Rac-specific guanine nucleotide exchange factor DOCK1 is a critical regulator of HER2-mediated breast cancer metastasis.
Laurin M; Huber J; Pelletier A; Houalla T; Park M; Fukui Y; Haibe-Kains B; Muller WJ; Côté JF
Proc Natl Acad Sci U S A; 2013 Apr; 110(18):7434-9. PubMed ID: 23592719
[TBL] [Abstract][Full Text] [Related]
13. Dock6, a Dock-C subfamily guanine nucleotide exchanger, has the dual specificity for Rac1 and Cdc42 and regulates neurite outgrowth.
Miyamoto Y; Yamauchi J; Sanbe A; Tanoue A
Exp Cell Res; 2007 Feb; 313(4):791-804. PubMed ID: 17196961
[TBL] [Abstract][Full Text] [Related]
14. RAC1
Lionarons DA; Hancock DC; Rana S; East P; Moore C; Murillo MM; Carvalho J; Spencer-Dene B; Herbert E; Stamp G; Damry D; Calado DP; Rosewell I; Fritsch R; Neubig RR; Molina-Arcas M; Downward J
Cancer Cell; 2019 Jul; 36(1):68-83.e9. PubMed ID: 31257073
[TBL] [Abstract][Full Text] [Related]
15. Targeting effector pathways in RAC1
Uribe-Alvarez C; Guerrero-Rodríguez SL; Rhodes J; Cannon A; Chernoff J; Araiza-Olivera D
Small GTPases; 2021 Jul; 12(4):273-281. PubMed ID: 32043900
[TBL] [Abstract][Full Text] [Related]
16. Identifying and treating ROBO1
Ferrari MG; Ganaie AA; Shabenah A; Mansini AP; Wang L; Murugan P; Davicioni E; Wang J; Deng Y; Hoeppner LH; Warlick CA; Konety BR; Saleem M
Prostate; 2020 Sep; 80(13):1045-1057. PubMed ID: 32687658
[TBL] [Abstract][Full Text] [Related]
17. RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.
De P; Carlson JH; Jepperson T; Willis S; Leyland-Jones B; Dey N
Oncotarget; 2017 Jan; 8(2):3072-3103. PubMed ID: 27902969
[TBL] [Abstract][Full Text] [Related]
18. RAC1 and melanoma.
Halaban R
Clin Ther; 2015 Mar; 37(3):682-5. PubMed ID: 25465943
[TBL] [Abstract][Full Text] [Related]
19. PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion.
Mense SM; Barrows D; Hodakoski C; Steinbach N; Schoenfeld D; Su W; Hopkins BD; Su T; Fine B; Hibshoosh H; Parsons R
Sci Signal; 2015 Mar; 8(370):ra32. PubMed ID: 25829446
[TBL] [Abstract][Full Text] [Related]
20. Transforming mutations of RAC guanosine triphosphatases in human cancers.
Kawazu M; Ueno T; Kontani K; Ogita Y; Ando M; Fukumura K; Yamato A; Soda M; Takeuchi K; Miki Y; Yamaguchi H; Yasuda T; Naoe T; Yamashita Y; Katada T; Choi YL; Mano H
Proc Natl Acad Sci U S A; 2013 Feb; 110(8):3029-34. PubMed ID: 23382236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
